Finally, the limitation of our study is related to limitations of national databases in combined searches, the lack or absence of studies showing the prevalence of thyroid dysfunction in some geographical areas such as north and east of Iran is another limitation. There was significant heterogeneity between the studies for thyroid dysfunction and given the available data, we Cevipabulin (TTI-237) could attribute this difference to geographic area, year of the study and sample size based on subgroup analysis. sample size (C), and quality of studies (D) 12884_2020_3040_MOESM5_ESM.tif (891K) GUID:?0FE1188B-8C89-4FD7-B9DA-D439CA5EA39E Additional file 6. Subgroup analysis of subclinical hypothyroidism in pregnant Iranian women based on geographic regions (A), year of studies (B), sample size (C), and quality of studies (D) 12884_2020_3040_MOESM6_ESM.tif (907K) GUID:?1A57FB4F-EA92-42A8-9E3C-9D8BB4B15E97 Additional file 7. Sensitivity analysis for prevalence of hyperthyroidism (A), clinical hyperthyroidism (B), subclinical hyperthyroidism (C)?in pregnant Iranian women 12884_2020_3040_MOESM7_ESM.tif (774K) GUID:?0C6EAAE1-DB51-4966-96FB-D26A9D341812 Additional file 8. Subgroup analysis of hyperthyroidism in pregnant Iranian women based on geographic regions (A), year of studies (B), sample size (C), and quality of studies (D) 12884_2020_3040_MOESM8_ESM.tif (878K) GUID:?45570CC4-73F3-49A1-9ECE-020778E8E229 Additional file 9. Funnel plot for thyroid function disorder (A), hypothyroidism (B), clinical hypothyroidism (C), subclinical hypothyroidism (D), hyperthyroidism (E), clinical hyperthyroidism (F), subclinical hyperthyroidism (G) and anti TPO (H) in pregnant Iranian women 12884_2020_3040_MOESM9_ESM.tif (1.3M) GUID:?1A8E54B9-EC0A-4D40-8D73-3772E950DE13 Data Availability StatementNot applicable. Abstract Background Thyroid dysfunction during pregnancy is associated with adverse outcomes for both mother and fetus. The present meta-analysis was conducted to evaluate thyroid dysfunction in Iranian pregnant women. Methods We registered this review at PROSPERO (registration number: CRD42020166655). The research steps in this systematic review and meta-analysis were performed according to the MOOSE protocol, and finally, reports were provided based on the PRISMA guidelines. The literature search was performed in October 2019 using the international online databases, including Web of Science, Ovid, Science Direct, Scopus, EMBASE, PubMed/Medline, Cochrane Library, EBSCO, CINAHL, Google Scholar as well as national databases Cevipabulin (TTI-237) were reviewed. Data were extracted after applying the inclusion and exclusion criteria and qualitative evaluation of the studies. I2 index and Q test were used to assess differences in studies. All analyses were performed using Comprehensive Meta-Analysis Software. Gestational age, Enzyme-linked immunosorbent assay, Radioimmunoassay, Immunoradiometric assay, Chemiluminescent immunoassay, immunoenzymometric assay, em anti-TPO Ab?anti-thyroperoxidase antibody /em Thyroid dysfunction The prevalence of thyroid dysfunction in 8420 Iranian pregnant women was 18.10% (95% CI: 13.89C23.25) in 11 studies. Heterogeneity was high among the studies: (Heterogeneity: I2?=?96.95%, em P /em ? ?0.001) (Fig.?2a). Sensitivity analysis by omitting one study showed that the overall estimate is robust (Fig. ?(Fig.22b). Open in a separate window Fig. 2 Prevalence of thyroid dysfunction in pregnant Iranian women (a) and sensitivity analysis (b) Subgroup analysis of thyroid dysfunction Subgroup analysis of thyroid dysfunction was significant in terms of geographical area ( em P /em ?=?0.014), year of the study ( em P /em ? ?0.001) and sample size ( em P /em ?=?0.020), but was not significant in terms of quality of studies ( em P /em ?=?0.177) (Additional?file?2). Hypothyroidism The prevalence of hypothyroidism (in 17 studies with a sample size of 15,208 people), clinical hypothyroidism (in 12 studies with a sample size of 11,920 people), and subclinical hypothyroidism (in 12 studies with a sample size of 11,920 people) in Iranian pregnant women was respectively estimated to be 13.01% (95% CI: 9.15C18.17), 1.35% (95% CI: 0.97C1.86) and 11.90% (95% CI: 7.40C18.57) (Fig.?3). Sensitivity analysis by omitting one study showed the overall results to be robust (Additional?file?3). Open in a separate window Fig. 3 Prevalence of hypothyroidism (a), clinical hypothyroidism (b), subclinical hypothyroidism in pregnant Iranian women Subgroup analysis of hypothyroidism Subgroup analysis of hypothyroidism prevalence was significant in terms of year of the study ( em P /em ?=?0.003) and sample size ( em P /em ?=?0.043), but was not significant in terms of geographical area ( em P /em ?=?0.573) and quality of Cevipabulin (TTI-237) studies ( em P /em ?=?0.210) (Additional?file?4). Subgroup analysis of clinical hypothyroidism prevalence was not significant in terms of geographic regions ( em P /em ?=?0.210), year of the study ( em P /em ?=?0.944), sample size ( em P /em ?=?0.885) Cevipabulin (TTI-237) and quality of studies ( em P /em ?=?0.132) (Additional?file?5). Subgroup analysis of subclinical hypothyroidism prevalence was significant in terms of year of Rat monoclonal to CD4/CD8(FITC/PE) the study ( em P /em ?=?0.006) and but was not significant in terms of geographical area ( em P /em ?=?0.196), sample size ( em P /em ?=?0.249) and quality of studies ( em P /em ?=?0.560) (Additional?file?6). Hyperthyroidism The prevalence of hyperthyroidism (in 11 studies with a sample size of 6697 people), clinical hyperthyroidism (in 6 studies with a sample size of 4738 people), and subclinical hyperthyroidism (in 6 studies with a sample size of 4738 people) in Iranian pregnant women was respectively estimated to be 3.31% (95% CI: 1.62C6.61), 1.06% (95% CI: 0.61C1.84) and 2.56% (95% CI: 0.90C7.05) (Fig.?4). Sensitivity analysis by omitting one study demonstrated the overall results to be robust (Additional?file?7). Open in a separate window Fig. 4 Prevalence of hyperthyroidism (a), clinical hyperthyroidism (b), subclinical hyperthyroidism in.